Related Announcements

PA-20-185 NIH Research Project Grant (Parent R01, no CT allowed)

PA-20-183, NIH Research Project Grant (Parent CT R01, CT only allowed)

PA-20-184 NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

PA-20-200 , NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

PA-20-196 , NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

PA-21-110 Pilot and Feasibility Studies inPreparation for Substance UsePrevention Trials (R34 Clinical Trial Optional)

Issued by

National Institute on Drug Abuse (NIDA)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

Purpose

The National Institute on Drug Abuse (NIDA) is issuing this Notice to encourage grant applications in research on the prevention of risky drug use behaviors and addiction.While there has been significant progress identifying and intervening on risk and protective factors for substance use, population-level impact of substance use prevention interventions has not?yet?been achieved. There continues to be a need for development and testing of substance use prevention strategies across the lifespan and for population subgroups at greater risk.

Research Objectives

NIDA is interested in?theory-driven prevention science?that spans intervention development and testing, as well as?services research, including dissemination and implementation science studies. Research?addressing?critical developmental?periods and transitions (e.g., transition to adulthood, transition out of foster care, job loss and housing instability, midlife/older adults) or targeting?interventions to?groups at increased risk of adverse outcomes (e.g., individuals with psychiatric co-morbidity, justice or child welfare-involved populations) is of priority. Intervention research may occur at any level (universal, selective, indicated, tiered), and across the lifespan. ?

NIDA prioritizes research that leads to the uptake and sustainability of effective practices and programs. To ensure interventions fit well into service settings, investigators are strongly encouraged to partner with stakeholders (e.g., those who the intervention is meant to benefit and those who will implement the intervention outside of a research study) at all phases of the intervention development and research process. NIDA is interested in interventions within a broad range of service settings, including justice, child welfare, social services, healthcare, education, and community settings. Finally, important to long term dissemination is the understanding of the economics of prevention. This may include intervention research that analyzes the costs of adopting evidence-based intervention strategies, studies of the costs relative to benefits of intervention delivery, and cost effectiveness research.

The research may include studies to:1) develop and test strategies to prevent the initiation of substance use, progression to substance use disorders,orto prevent substance use-related conditions such as HIV; 2) develop and test processes or strategies to implement, scale,and sustain evidence-based prevention in community, practice, and service systems;and,3) develop methods to conduct prevention science.Primary outcomes of interest for submitted applications include preventing initiation of substance use, misuse, and progression to disorder, as well as prevention of HIV infection.

This NOSI encourages, but is not limited to, research applications in the following areas:

Intervention Development and Testing:

• Efficacy and effectiveness research to examine intervention effects on initiation of drug use and progression from use to misuse to disorder. Studies should further our understanding of mechanisms of action for preventing risky substance use and addiction. For example, by studying moderators and mediators of prevention effects and informingtailoring and optimizing interventions for settings and populations.

• Translational intervention development research that uses findings from epidemiology, cognitive science, neuroscience, genetics and other diverse fields to develop and test prevention interventions.

• Research on intervention strategies to reduce harm, such as preventing the transition from electronic nicotine device use to combustible cigarette use, preventing the initiation of injection drug use, preventing simultaneous use of psychoactive substances, or preventing substance use while operating a vehicle or machinery.

• Methodology research for designing, testing and optimizing prevention interventions and policies; Analytic models and statistical techniques for analyzing complex data and for testing mediation and moderation in longitudinal intervention studies.

• Research that examines structural, environmental, or policy approaches to prevention

• Studies to intervene on upstream social determinants of health and address multiple levels of influence as defined by the National Institute on Minority Health and Health Disparities (NIMHD) research framework.

• Research that addresses U.S. Preventive Services Task Force (USPSTF)- and Community Preventive Services Task Force (CPSTF)- insufficient evidence statements as related to substance use and substance use disorders.

Prevention Services Research:

• Research that develops and tests strategies, frameworks, or tools to implement and sustain, evidence-based prevention interventions in settings and systems

• Research on systems-level scale-up of evidence-based programs and system capacity (including workforce) to deliver interventions.

• Studies of strategies for dissemination of evidence-based prevention services

• Studies to identify barriers and facilitators of implementing screening and referral to prevention services within service systems.

• Research on access to and engagement in prevention services, particularly for hard-to-reach and underserved populations.

Interested investigators are encouraged to reach out to relevant program officers prior to submission.

Application and Submission Information

This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through May 8, 2025.

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice.

• PA-20-185 NIH Research Project Grant (Parent R01, no CT allowed)
• PA-20-183, NIH Research Project Grant (Parent CT R01, CT only allowed)
• PA-20-184 NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
• PA-20-200 , NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
• PA-20-196 , NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
• PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
• PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
• PA-21-110 Pilot and Feasibility Studies inPreparation for Substance UsePrevention Trials (R34 Clinical TrialOptional)

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

• For funding consideration, applicants must include NOT-DA-23-001 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.

Inquiries

Amy B. Goldstein, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301.827.4124
Email: [email protected]